Cost-effective analyses in Breast Cancer Research and Treatment

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.115, Iss.2, 2009-05, pp. : 221-222

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Erratum to: Editorial: Cost-effective analyses in Breast Cancer Research and Treatment

By Lippman Marc Ethier Stephen Hayes Daniel

Breast Cancer Research and Treatment, Vol. 129, Iss. 1, 2011-08 ,pp. : 293-293

Springer Publishing Company

Access to resources Recommend Favorite

Adjuvant fluorouracil, epirubicin and cyclophosphamide in early breast cancer: Is it cost-effective?

By Norum Jan Holtmon Mari

Acta Oncologica, Vol. 44, Iss. 7, 2005-10 ,pp. : 735-741

Informa Healthcare

Access to resources Recommend Favorite

Adjuvant Cyclophosphamide, Methotrexate, Fluorouracil (CMF) in Breast Cancer: Is it Cost-effective?

By Norum Jan

Acta Oncologica, Vol. 39, Iss. 1, 2000-04 ,pp. : 33-39

Informa Healthcare

Access to resources Recommend Favorite

Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis

By Rocchi A. Verma S.

Supportive Care in Cancer, Vol. 14, Iss. 9, 2006-09 ,pp. : 917-927

Springer Publishing Company

Access to resources Recommend Favorite

Breast Cancer Research and Treatment

Breast Cancer Research and Treatment, Vol. 79, Iss. 2, 2003-05 ,pp. : 281-285

Springer Publishing Company

Access to resources Recommend Favorite